Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Weitang

Explore full profile

Developing diabetes management platform

Huangpu, ChinaFounded 2012Health Tech & Medtech
Valuation $50–100M Last recorded · 2016
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Weitang and the history behind them.

About Weitang

Weitang, formerly known as Boyibang, operated as a digital health entity with a specific focus on the diabetes management sector. The company was established in 2012 and was headquartered in Shanghai, China. Weitang's business model revolved around providing a comprehensive digital platform designed for both individuals with diabetes and their healthcare providers.

The core of Weitang's offering was a mobile and online application that enabled users to meticulously track crucial health data. This included monitoring blood sugar levels, logging food consumption, recording physical exercise, and managing medication schedules. The platform's objective was to empower patients with tools for better self-management and to provide clinicians with valuable data to support treatment. A clinical study highlighted the application's efficacy, demonstrating that its use led to significant improvements in key health markers like HbA1c and blood glucose, as well as enhanced patient knowledge and self-care practices.

The company secured capital to support its operations, including a Series A funding round of $5 million in September 2014, followed by a subsequent Series B round. Despite its promising start and the clinical validation of its platform, publicly available investment data indicates the company is now out of business.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2012
Headquarters
Huangpu, China
Open positions
None listed
Dealroom signal
51.0/100
Industry
Health
Sub-industry
Health Platform
Sector
Health Tech & Medtech, Personal Health, Diabetes, Hard Tech
Business model
SaaS
Client focus
b2b

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Jan 2016 $10M $40M Yidu Tech —
ANGEL✓Equity / VC Oct 2013 $700K $2.8M Wu Jiong —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Weitang website traffic

Latest recorded traffic for Weitang is 150 monthly website visits, down 25% over the last three months.

Latest monthly visits150 3-month web change-25%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Wu Jiong

Series A1 investor entered at this stage

  • Yidu Tech
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Huangpu HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Weitang on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Weitang’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.